Understand the source comparison
Best Peptides for Crohn's Disease: Comparison
BPC-157 VEGF receptor activation, angiogenesis stimulation, mucosal healing Complete ulcer healing in 14 days in TNBS colitis models; promotes capillary formation in damaged intestinal tissue Subcutaneous injection or oral (gastric-resistant formulation) Human
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF receptor activation, angiogenesis stimulation, mucosal healing
- Complete ulcer healing in 14 days in TNBS colitis models; promotes capillary formation in damaged intestinal tissue
- Subcutaneous injection or oral (gastric-resistant formulation)
- Human trial data limited to case reports; optimal dosing not established in IBD populations
- Most compelling evidence for direct tissue repair; addresses the healing deficit biologics don't target
- Thymosin Alpha-1 (Tα1)
- T-cell differentiation modulation, Th1/Th2 rebalancing, dendritic cell maturation
- Reduced disease activity index by 6.2 points vs placebo; 68% remission when combined with infliximab vs 41% infliximab alone
- Subcutaneous injection
- Requires ongoing administration; effects diminish after cessation; cost comparable to biologics in some markets
- Best suited for patients with Th1-dominant inflammation who plateau on anti-TNF monotherapy
- KPV (Lys-Pro-Val)
- NF-κB inhibition, intracellular anti-inflammatory signaling, IL-8 suppression
- 73% reduction in IL-8 secretion in inflamed epithelial cells; 82% reduction in macroscopic colitis damage in animal models
- Oral (enteric-coated) or subcutaneous
- Oral bioavailability challenges; no large-scale human trials in IBD; mechanism targets symptoms more than structural repair
- Strongest theoretical rationale for upstream inflammation control; practical application limited by delivery constraints
- Thymalin
- Polypeptide thymic extract containing Tα1 and related fractions; immune system regulation
- Improved immune markers in autoimmune models; modulates cytokine balance similar to isolated Tα1
- Intramuscular injection
- Less characterised than isolated Tα1; variable composition across batches
- Broader immunomodulatory profile than isolated Tα1 but less standardised for research purposes